All participants in the trial improved, but those on higher doses had about 37 minutes less “off” time each day than those taking the placebo, and about 94 minutes less “off” time before the study began.They also gained 36 extra minutes of “on” time without troublesome dyskinesia compared to the placebo group.No serious adverse effects were reported. The drug developers will now approach US health regulators for approval. If talks go smoothly, UK health regulators would follow.Dr Lynsey Bilsland, managing director of Parkinson’s UK’s global drug development programme, said: “Right now, no drug can stop or slow the progression of Parkinson’s.”These latest results from the trial of SNT-4728 [solengepras] are encouraging, showing an improvement in movement symptoms in a population that has yet to be diagnosed with Parkinson’s in such a short time.”